Document Detail

PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
MedLine Citation:
PMID:  22402789     Owner:  NLM     Status:  Publisher    
AIM: The aim of this paper was to prospectively evaluate FDG PET/CT in the assessment of metabolic response to neoadjuvant chemotherapy and correlation with tumor cellularity in locally advanced breast cancer. METHODS: Images were acquired with a PET/CT scanner in 50 patients at baseline and after completion of treatment, just before surgery. All findings were confirmed by histopathological analysis. PET/CT quantification (SUVmax) at baseline and after finishing neoadjuvant chemotherapy (4 cycles of epirubicin + cyclophosphamide +/- taxanes) were compared using RECIST criteria and Miller & Payne (M&P) scale. RESULTS: Baseline mean tumor size was 4.4±1.6 cm. Thirty eight patients were considered responders and 12 nonresponders. According to M&P scale, 10 patients had good prognosis (grades 4-5) and 40 patients had bad prognosis (grades 1-3). All patients with grade 5 M&P had no significant postchemotherapy FDG uptake. Patients with bad prognosis had lower SUVmax variation (∆SUVmax) than patients with good prognosis (60.7% vs. 80.5%, P=0.0016). ∆SUVmax was lower in nonresponders than in partial responders according to RECIST criteria (38.9% vs. 67.6%, p<0.001), and was also lower in partial responders than complete responders (67.6% vs. 85.4%, P=0.005). A cut-off ∆SUVmax value of 52% differentiates responders from nonresponders with a sensitivity of 86% and a specificity of 90%. Probability densities of the ∆SUVmax (%) for stable disease (<45), partial (>45 to <82) and complete response (>82) showed an overall accuracy of 78% (Weighted Kappa=0.74). CONCLUSION: PET/CT is useful to monitor response to neoadjuvant chemotherapy in locally advanced breast cancer. ∆SUVmax on PET/CT correlates with tumor cellularity after completion of neoadjuvant chemotherapy.
J Duch; D Fuster; M Muñoz; P L Fernández P L Paredes; P Paredes; M Fontanillas; K Skaltsa; B Domènech; F Lomeña; F Pons
Related Documents :
24327459 - Diagnostic utility of central node necrosis in predicting extracapsular spread among or...
2039319 - Primary cardiac sarcomas.
22600449 - Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prosp...
8407399 - Long-term results of a prospective randomized trial of adjuvant brachytherapy in the ma...
9758339 - Phase ii study of high-dose thiotepa and hematopoietic stem cell transplantation in chi...
22826139 - Analysis of multi-stage treatments for recurrent diseases.
14760109 - Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase ii trial and pred...
12508269 - Childhood and adolescent large-cell lymphoma (lcl): a review of the children's cancer g...
7453449 - Thyroid carcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-09
Journal Detail:
Title:  The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...     Volume:  -     ISSN:  1824-4785     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101213861     Medline TA:  Q J Nucl Med Mol Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Nuclear Medicine Department, Barcelona Clinical Provincial Hospital, Barcelona, Spain -
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reproducibility and variability of global and regional dyssynchrony parameters derived from phase an...
Next Document:  Cranial hypertrophic pachymeningitis secondary to neurocysticercosis.